Volume : IX, Issue : V, May - 2020

A Review of COVID-19 Convalescent Plasma Clinical Trials and Protocols for SARS-CoV-2

Jianli Cui, Youfu Ke

Abstract :

Context: COVID-19 has developed into a public health emergency of international concern. Treatment of COVID-19 is limited to supportive care with no therapies or vaccines approved. It is constructive to conduct a review of COVID-19 convalescent plasma (CCP) trials and protocols for SARS-CoV-2. Evidence Acquisition: 8 databases were searched on May 1 2020, including CNKI, PubMed, Cochrane Liary, etc. with search fields "Title Abstract Keyword" of "Convalescent plasma AND COVID-19". The outcome of interest was clinical benefits, mortality, viral load, viral antibody titers, adverse events as well as RCT trials protocols for COVID-19. Results: The search retrieved five completed clinical trials and nine clinical research protocols for SARS-CoV-2. The five finished trials involved 27 patients with biases due to non-RCT methodology. All subjects after CCP demonstrated normalized temperature, absorbed lung lesions, resolved ARDS, removed ventilation with decreased viral load and increased antibody. The nine RCT protocols are randomized clinical studies with NCT04344535, NCT04345289 and NCT04323800 in masking, and the rest in open-label. The other eight trials will verify the efficacy and safety of CCP to treat COVID-19 apart from NCT04323800 to prevent COVID-19. NCT04344535, NCT04323800, NCT04346446 employ standard donor plasma in controlled groups, in contrast to the standard of care with NCT04348656, NCT04342182, NCT04333251 and NCT04345523; NCT04332835 adds Hydroxychloroquine 800 mg for ten days to both treatment and control groups; NCT04345289 is a complicated 6-armed placebo-controlled trial. Primary and secondary outcome measures can be summarized as ㈠ charges of 7-point ordinal scale; ㈡ charges in SARS-CoV-2 RNA, anti-SARS-CoV-2 titers, CRP, IL-6 etc. Conclusions: CCP can normalize temperature, absorb lung lesions, resolve ARDS, remove ventilation, and is an effective and safe option to treat COVID-19. The nine RCT trials will establish the efficacy of CCP for COVID-19 from the perspective of evidence-based medicine.

Keywords :

Article: Download PDF    DOI : https://www.doi.org/10.36106/gjra  

Cite This Article:

A REVIEW OF COVID-19 CONVALESCENT PLASMA CLINICAL TRIALS AND PROTOCOLS FOR SARS-COV-2, Jianli Cui, Youfu Ke GLOBAL JOURNAL FOR RESEARCH ANALYSIS : Volume-9 | Issue-5 | May-2020

Number of Downloads : 508

References :